SAN FRANCISCO – Thermo Fisher Scientific Inc. has entered an agreement with Illumina Inc. for DNA and RNA sequencing technology, and will continue to integrate its newest acquisition, Patheon, this year. Fisher also plans to launch a comprehensive clinical mass spectrometry, executives reported at the J.P. Morgan Healthcare Conference. Read More
